Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
In patients who receive neoadjuvant chemo-immunotherapy( 3 cycles of PD1 + chemo) for resectable NSCLC, what is your post operative approach after successful R0 resection?
Related Questions
Would you offer any additional adjuvant therapy after platinum based chemotherapy for patients with resected PD-L1 positive Stage II-III lung adenocarcinoma with EGFR exon 20 insertions?
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?
What chemotherapy regimens would be appropriate for cisplatin-ineligible patients to receive concurrently with definitive radiotherapy for locally advanced (inoperable) thymic carcinoma?
What are best practices for oncologists during the national platinum shortage?
What factors would determine which currently approved agent to use as a first line treatment for a stage IV ROS-1 fusion patient with the approval of repotrectinib?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
How do you define an adequate EBUS when staging NSCLC?